Lupin Share Price (LUPIN)
as on
| Source : NSE
Lupin Stock Performance
as on August 26, 2025 at 4:01 PM IST
Day's Low
Day's High
₹1,911₹1,963.1
0.71%
Downside
2.00%
Upside
52 Week's Low
52 Week's High
₹1,795.2₹2,402.96.72%
Downside
24.85%
Upside
| Market Stats | |
| Previous Close | ₹1,966.30 |
| Open | ₹1,963.10 |
| Volume | 15.23L |
| Upper Circuit | ₹2,162.90 |
| Lower Circuit | ₹1,769.70 |
| Day's Low | ₹1,911 |
| Day's High | ₹1,963.1 |
| 52 Week Low | ₹1,795.2 |
| 52 Week High | ₹2,402.9 |
| Returns % | |
| 1 Month Return | + 0.3 % |
| 3 Month Return | -1.06 % |
| 1 Year Return | -7.08 % |
| 3 Year Return | + 201.26 % |
| 5 Year Return | + 100.9 % |
Lupin Stock Fundamentals & Key Indicators
Check Lupin market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹89,810.23 Cr
Return on Equity (ROE)
17.7
PE Ratio (TTM)
24.25
Return on capital employed (ROCE)
21.32
Industry PE ratio
43.85
Beta (LTM)
0.8
P/B Ratio
3.81
Dividend Yield
0.59
PEG Ratio
0.77
Quarterly Earnings Growth YOY
51.63
EPS (TTM)
72.41
Sector
Pharmaceuticals
Book Value
376.77
Technical Analysis
Bearish
View Technical Analysis
Lupin Stock's Interest Amongst Investors
Lupin Stock Valuation
Track how Lupin P/E has moved over time to understand its valuation trends.
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (24.25x)
August 25, 2025
Industry (43.85x)
August 25, 2025
Highest (517.33x)
December 2, 2022
Today’s Price to Earnings Ratio: 24.25x
Lupin Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Lupin.
based on 37 analysts
59.46%
Buy
35.14%
Hold
5.41%
Sell
59.46% of analysts recommend a 'BUY' rating for Lupin. Average target price of ₹2229.14
Source: S&P Global Market Intelligence
Lupin Share Price Target
Get share price movements and forecasts by analysts on Lupin.
Lupin price forecast by 37 analysts
Upside of13.37%
High
₹2626
Target
₹2229.14
Low
₹1896
Lupin target price ₹2229.14, a slight upside of 13.37% compared to current price of ₹1924.6. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin revenue growth forecast
Expected growth rate Q1, FY2027:17.86%
Forecast
Actual
Including amortisation and stock based compensations
Lupin EPS growth forecast
EPS estimate Q1, FY2027:23.67%
Forecast
Actual
Source: S&P Global Market Intelligence
Lupin Ltd Financial Results
Get the annual and quarterly financial summary of Lupin Ltd, including revenue, profit, loss and more.
Lupin Earnings and Dividends
View detailed summary of the earnings and dividend history of Lupin.
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 52.13% since last year same period to ₹1,219.03Cr in the Q1 2025-2026. On a quarterly growth basis, Lupin Ltd has generated 57.8% jump in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2025
In the quarter ending March 2025, Lupin Ltd has declared dividend of ₹12.00 per share on 14 May 2025 - translating a dividend yield of 0.61%.
Read More about Dividends
Indices Featuring Lupin Stock
Check stock indices that include Lupin.
Lupin Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Lupin.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.9% | ||
| Foreign Institutions | 21.25% | ||
| Mutual Funds | 19.35% | 10.29 | |
| Retail Investors | 6.28% | 1.22 | |
| Others | 6.21% |
Lupin Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Lupin with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 89,810.23 | 20.18% | 0.63 | 3,306 | 22,707 | |
| BUY | 12,041.24 | -7.95% | 0.52 | 413 | 2,013 | |
| BUY | 62,543.09 | 4.6% | 0.60 | 3,483 | 31,723 | |
| HOLD | 1,02,952.83 | 32.65% | 0.61 | 4,614 | 23,241 | |
| BUY | 66,980.00 | 17.2% | 0.00 | 1,414 | 6,445 |
Lupin News & Key Events
Latest news and events in one place to help you make informed investing decisions in Lupin.
Lupin Launches Bosentan Tablets in US Market - 20 Aug, 2025
Lupin Limited has launched Bosentan Tablets for Oral Suspension in the US, benefiting from 180-day exclusivity. The product targets pediatric patients with pulmonary arterial hypertension, with estimated annual sales of $10 million.Lupin Partners with Sandoz for Biosimilar Commercialization - 12 Aug, 2025
Lupin Limited has partnered with Sandoz Group AG to market its biosimilar Ranibizumab across various regions. Lupin will handle manufacturing and regulatory submissions, while Sandoz manages commercialization rights in designated markets.Lupin Launches Glucagon Injection, Shares Rise - 11 Aug, 2025
Lupin Limited launched Glucagon for Injection USP, targeting a $122 million market in the U.S. Shares rose 1.04% following the announcement, reflecting positive investor sentiment.Lupin Receives Positive Target Price Upgrades - 08 Aug, 2025
Lupin's strong Q1FY26 results led Nomura to set a target price of Rs 2,350, while Emkay Global raised its target to Rs 2,500, highlighting sustained growth and margin improvements.Lupin Reports Strong Q1, Faces Tariff Concerns - 06 Aug, 2025
Lupin's Q1 FY26 results show a 52% profit increase, prompting a 3% stock rise. However, looming US tariffs create market pressure, leading to cautious sentiment.Lupin Reports Strong Q1 Results with Profit Surge - 05 Aug, 2025
Lupin Ltd posted a robust Q1FY26, with net profit rising 52.1% YoY to ₹1,219 crore, driven by strong sales in the US and India. Revenue increased by 11.9% to ₹6,268 crore, and EBITDA surged 39.2% to ₹1,727 crore, reflecting operational efficiencies and strategic investments.Lupin Initiates Recall of Blood Pressure Medication - 27 Jul, 2025
Lupin Pharmaceuticals is recalling 58,968 bottles of Lisinopril and Hydrochlorothiazide tablets due to a product mix-up. The recall, classified as Class II, affects a lot manufactured at their Nagpur facility.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 17.55% to 19.35% in Jun 2025 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 5.72K Cr → 6.34K Cr (in ₹), with an average increase of 9.8% per quarter
- POSITIVE IMPACT
Price Rise
In the last 3 years, LUPIN stock has moved up by 201.3%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 772.52 Cr → 1.21K Cr (in ₹), with an average increase of 36.6% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 6.20% to 6.28% in Jun 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 26.8% return, outperforming this stock by 33.9%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 46.92% to 46.90% in Jun 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 21.46% to 21.25% in Jun 2025 quarter
About Lupin Ltd
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Revenue: ₹6,163.75Cr as on June 2025 (Q1 FY26)
Net Profit: ₹1,221.46Cr as on June 2025 (Q1 FY26)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin Ltd |
| Industry | Pharmaceuticals |
| CEO | M D Gupta |
| E-voting on shares | Click here to vote |
Mutual Funds that own Lupin Stock
Check out the Mutual Funds with significant holdings in Lupin.
FAQs
What is Lupin share price today?
Lupin share price today stands at ₹1924.6, Open: ₹1963.1, Previous Close: ₹1966.3, High: ₹1963.1, Low: ₹1911, 52 Week High: ₹2402.9, 52 Week Low: ₹1795.2 as on .
How to buy Lupin shares ?
To buy Lupin shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for LUPIN or Lupin Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Lupin shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Lupin?
Today's traded volume of Lupin is 15.23L. Which means that 15.23L shares of Lupin were bought and sold on the stock market during today's trading session.
What is Lupin's market cap today?
Today's market capitalisation of Lupin is ₹89,810.23 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Lupin?
Lupin’s 52 week high is ₹2402.9 and 52 week low is ₹1795.2. The current share price of Lupin is ₹1924.6, which is -19.91% down from its 52 week high and 7.21% up from its 52 week low.